期刊
CHINESE CLINICAL ONCOLOGY
卷 8, 期 5, 页码 -出版社
AME PUBLISHING COMPANY
DOI: 10.21037/cco.2019.08.08
关键词
Metastatic colorectal cancer (mCRC); molecular heterogeneity; biomarkers
类别
Colorectal cancer remains one of the most common cancers worldwide and is almost uniformly fatal for those with metastatic disease. Despite this, there is an increasing number of treatments and overall survival has been increasing. Utilizing increasing knowledge of tumor biology, there have been 13 new FDA drug approvals and 5 additional drugs that appear on the National Comprehensive Cancer Network (NCCN) guidelines that await FDA approval since 2002. Still, there is great need for many patients for additional treatment options. In the following text, we review our current clinical and molecular knowledge as it pertains to treatment of patients with metastatic colorectal cancer and future directions regarding therapeutic vulnerabilities.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据